Skip to main content
. 2015 Nov 9;99(4):363–369. doi: 10.1002/cpt.269

Figure 1.

Figure 1

Cumulative incidence of time to bilirubin‐associated discontinuation of atazanavir stratified by UGT1A1 genotype in AIDS Clinical Trials Group protocol A5257 (adapted from ref. 32). Top panels: Lines estimate the cumulative incidence of time to bilirubin‐associated discontinuation of atazanavir, stratified by UGT1A1 rs887829 genotype and self‐reported race/ethnicity. P values are given by Gray's test for testing equality of cumulative incidence functions. Dashed red lines represent rs887829 T/T, dotted green lines rs887829 C/T, and solid blue lines rs887829 C/C. Bottom panels: Proportions of individuals in this analysis with rs887829 T/T, C/T, and C/T genotypes.